ORIGINAL Conclusions: The diagnostic properties of electrophysiological screening vary over time. Abnormal CMAP documented early during critical illness carries information about longer-term outcome, which should be further investigated mechanistically.
Purpose Abstract: Muscle weakness in long-stay ICU patients contributes to 1-year mortality. Whether electrophysiological screening is an alternative diagnostic tool in unconscious/uncooperative patients remains unknown. We aimed to determine the diagnostic properties of abnormal compound muscle action potential (CMAP), sensory nerve action potential (SNAP), and spontaneous electrical activity (SEA) for Medical Research Council (MRC)defined weakness and their predictive value for 1-year mortality. Methods: Data were prospectively collected during the EPaNIC trial (ClinicalTrials.gov: NCT00512122). First, sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of abnormal CMAP, SNAP, and SEA for weakness were determined. Subsequently, association between 1-year mortality and abnormal findings on electrophysiological screening was assessed by univariate and multivariate analyses correcting for weakness and other risk factors and the prediction model involved only a development phase. Results: A total of 730 patients were electrophysiologically screened of whom 432 were tested for weakness. On day 8, normal CMAP excluded weakness with a high NPV (80.5 %). By day 15, abnormal SNAP and the presence of SEA had a high PPV (91.7 and 80.0 %, respectively). Only a reduced CMAP on day 8 was associated with higher 1-year mortality [35.6 vs 15.2 % (p \ 0.001)]. This association remained significant after correction for weakness and other risk factors [OR 2.463 (95 % CI 1.113-5.452), p = 0.026]. Also among conscious/cooperative patients without weakness, reduced CMAP was independently associated with a higher likelihood of death occurring during 1 year [HR 2.818 (95 % CI 1.074-7.391), p = 0.035].
Introduction
Critically ill patients often develop weakness due to functional and structural alterations in nerves, muscles, or both. The diagnosis of ICU-acquired neuromuscular disorders is primarily based on clinical strength assessment, using the Medical Research Council (MRC) sum-score [1, 2] . This score quantifies strength in six muscle groups bilaterally, with a summed score below 48 indicating clinically relevant weakness [2, 3] . About 50 % of patients with sepsis, multiple organ failure, or requiring prolonged mechanical ventilation suffer from weakness [4] . Association studies suggested that weakness is a burden in the acute [3, [5] [6] [7] [8] and chronic phase of critical illness [9, 10] . Recently, we showed that weakness present after 1 week of critical illness contributes to ICU and hospital morbidity, increased hospitalization costs, and 1-year mortality [8] .
The MRC-based diagnosis requires patients to be awake and cooperative. Between 22 and 53 % of patients [3, 6, 7, 11] therefore remain clinically not assessable in the ICU. Electrophysiological screening including the quantification of compound muscle action potentials (CMAP), sensory nerve action potentials (SNAP), and the presence of spontaneous electrical activity (SEA) could serve as an alternative diagnostic tool in such cases ( Fig. 1 ) [12] [13] [14] . However, diagnostic properties of abnormal CMAP, SNAP, and SEA for weakness in the ICU are not well characterized. Additionally, electrophysiological features could reflect other pathophysiological alterations, evoked by critical illness or pre-existing, that could be important for survival, related to or independent of weakness [15] .
In this large prospective study, we determined the diagnostic properties of abnormal CMAP, SNAP, and SEA for MRC-defined weakness after 1 and 2 weeks of critical illness. We hypothesized that abnormal CMAP, SNAP, or SEA upon electrophysiological screening 1 week after ICU admission relate to longer-term mortality, and assessed whether these associations depend on the presence of weakness as well as on baseline characteristics and exposure to ICU-related risk factors prior to electrophysiological screening. This is a development-only phase of a prognostic prediction model and aimed to specifically address the independent role of electrophysiological characteristics for 1-year mortality [16] .
Methods
The trial protocol and consent forms were approved by the institutional ethical review board (ML4190).
Patients
This study is a preplanned subanalysis of the EPaNIC trial [17] , which included 4640 patients and examined early versus late administration of parenteral nutrition to supplement insufficient enteral nutrition in critically ill patients [18] . Identification of risk factors for 1-year mortality (see ''Statistical analyses'') was done in the total EPaNIC population.
From October 2008 onwards, patients requiring intensive care for at least 8 days, henceforth referred to as longstay patients, received systematic electrophysiological screening once weekly, until ICU discharge or death. We a priori selected these patients for screening because of their increased risk of developing weakness. The first evaluation was planned on day 8 (±1 day for feasibility reasons). As it is unknown to what extent ICU patients with favorable clinical evolution have electrophysiological abnormalities, we also included a random sample of short-stay patients discharged alive from the ICU but still in hospital at day 8. The random sample was computer-generated in a 1:10 ratio and stratified according to diagnostic admission categories. These patients received electrophysiological screening on day 8 ± 1 on the ward (Fig. 2 ). From December 2008 onwards, MRC sum-score was systematically assessed three times weekly in awake long-stay patients [8, 11] . Also here, a random sample of short-stay patients was included. Patients with neuromuscular disorders identified prior to ICU admission, or in whom this was the reason for ICU admission, were excluded (see electronic supplementary material, ESM). Other exclusion criteria were patient refusal, unavailability of patient/assessor at planned examination, and decrement on repetitive nerve stimulation, indicating neuromuscular blocking.
Electrophysiological tests
For nerve conduction studies, one standard motor and one sensory nerve were evaluated in both upper and lower limbs unilaterally. We defined reduced CMAP and SNAP when below the lower limit of normal in both nerves of both limbs [19] . Needle electromyography in rest was performed unilaterally in one standard proximal and one distal muscle in both upper and lower limbs. Abundant SEA was defined as the presence of sustained fibrillation potentials and/or positive sharp waves in at least two muscles of at least two limbs (see ESM).
MRC sum-score
The MRC sum-score was evaluated as described [11, 20] and assessed by physiotherapists blinded for electrophysiological data (see ESM).
Nerve conduction studies

Motor nerve conduction studies:
A peripheral nerve is stimulated and the evoked compound muscle action potential (CMAP) is recorded with use of surface electrodes overlying a muscle supplied by that nerve. CMAP is reduced in neuropathy and myopathy.
Median nerve motor study (CMAP)
Sensory nerve conduction studies:
A peripheral nerve is stimulated and the evoked sensory nerve action potential (SNAP) is obtained with surface electrodes from a purely sensory distal part of the stimulated nerve. SNAP is reduced in neuropathy. As absolute values of SNAPs are much smaller than absolute values of CMAPs, SNAPs are more affected by limb edema.
Median nerve sensory study (SNAP)
Electromyography
Electrical muscle activitiy in rest:
This is registered with use of a concentric needle. Abnormal spontaneous electrical activity (SEA) occurs as fibrillation potentials and/or positive sharp waves and may be present in case of denervation or muscle necrosis. Results were compared using Mann-Whitney U test, Chisquare test, logistic regression analysis, and Cox proportional hazard analysis. Differences were considered significant when two-sided p values were at most 0.05. The two primary outcomes were (1) sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) of abnormal CMAP, SNAP, and SEA for weakness (MRC sum-score less than 48) and (2) the predictive value for 1-year mortality of abnormal electrophysiology results, documented at first evaluation. Data on index and reference tests are reported according to the Standards for Reporting of Diagnostic Accuracy [21] .
Electromyography of the vastus lateralis of the quadriceps muscle
First, incidence of abnormal CMAP, SNAP, and SEA was determined in the total screened population and in the 432 cooperative patients tested for weakness. In the latter subgroup, sensitivity, specificity, PPV, and NPV of abnormal CMAP, SNAP, and SEA for weakness were analyzed at the first and second electrophysiological evaluation. Second, association between 1-year mortality and abnormal findings on the first electrophysiological screening was assessed by univariate analysis and, when significant, multivariate analyses were performed correcting for weakness and other risk factors. Baseline risk factors for 1-year mortality, risk factors to which patients were exposed in ICU prior to first electrophysiological assessment (including new infection, treatment with neuromuscular blocking agents, duration of corticosteroid administration, and duration of mechanical ventilation), and the site of electrophysiogical testing were identified by univariate regression analysis (p \ 0.2) (Table E2) .
Multivariate logistic regression analysis of the screened population was performed in two steps, first assessing the independent predictive value of any abnormal electrophysiological result corrected for weakness, and second further correcting for other pre-existing and ICU-acquired risk factors. Risk factors were assigned to the final model with use of a backward method (likelihood ratio, probability for entry 0.1, removal 0.2). Model performance is reported with the Hosmer-Lemeshow test, c-statistic, and visualized by the ROC curve. To exclude excessive correlation that might prevent obtaining useful information we checked correlation coefficients [22] and performed a forward (likelihood ratio) multiple regression analysis [23] . As MRC sum-score below 48 remains an arbitrary limit, we planned a post hoc determination of its optimal cutoff for 1-year mortality and used this to repeat the analysis.
To further examine whether weakness and electrophysiology hold different information for long-term outcome, patients were categorized into four groups according to MRC and electrophysiology. Cox proportional hazard analysis for 1-year survival was performed 
Results
Patient characteristics
Electrophysiological screening was performed in 730 patients ( Fig. E1 in the ESM) on median day 8 (IQR . This comprised 88 short-stay and 642 long-stay patients. Baseline and outcome variables are depicted in Table 1 and Table E3 (ESM).
In 432 patients, MRC sum-score was also obtained. In this subset, electrophysiological testing was performed on day 8 (IQR 8-9) and MRC sum-score on day 10 (IQR [8] [9] [10] [11] [12] [13] [14] . The delay from electrophysiological testing up to the clinical evaluation was 2 days (IQR 0-6). This subgroup clearly differed from the subgroup that could not be clinically tested (Table 1) .
Diagnostic properties of electrophysiological screening for clinical weakness
In the total population of 730 patients, abnormal CMAPs, SNAPs, and SEA occurred in respectively 75.5, 11.1, and 20.4 % of patients (Table 2) . Inevitably, analysis of diagnostic properties of these features was performed in the 432 patients who received both MRC and electrophysiology assessment on day 8. The incidence of abnormal CMAP and SEA was somewhat lower in the cooperative subgroup with MRC sum-score (Table 2) .
Reduced CMAP on day 8 had high sensitivity (88.6 %) and high NPV (80.5 %) but low specificity (41.0 %) for weakness at first examination ( Table 2) . Reduced SNAP had a low incidence and very low sensitivity for detecting weakness (13.6 %), although it was highly specific (93.5 %). Abnormal SEA exhibited a similar pattern with specificity of 89.3 % but only 20.7 % sensitivity. No single or combined (data not shown) electrophysiological feature exhibited high sensitivity and high specificity for detecting weakness on day 8.
When also taking the second electrophysiological screening on day 15 (IQR 15-15) into account, the incidence of electrophysiological abnormalities increased. In multivariate analysis, adding weakness to the model revealed that both abnormal CMAP and weakness were independently associated with 1-year mortality ( Table 3) . Further adding the other risk factors, including baseline risk factors (e.g., co-morbidities), ICU exposures, and site of electrophysiological assessment did not alter this result (final OR for abnormal CMAP 2.463, 95 % CI 1.113-5.452, p = 0.026 and for weakness 1.955, 95 % CI 1.116-3.425, p = 0.019). None of the risk factors to which patients were exposed in ICU prior to electrophysiological screening remained associated with 1-year mortality in the multivariate model (Table 3 ) with a Hosmer-Lemeshow test p = 0.147 and c-statistic = 0.779 (95 % CI 0.730-0.829) ( Fig. E2 in the ESM) . The forward regression model retained the same factors as the backward model. Sensitivity analyses, using the optimal discriminating MRC sum-score cutoff for 1-year mortality of 53 yielded similar results (data not shown).
Cox proportional hazard analysis of survival within the first year following ICU admission further confirmed that patients with reduced CMAP but no weakness had a higher likelihood for earlier death (HR 2.818, 95 % CI 1.074-7.391, p = 0.035) as compared to patients with normal CMAP and no weakness. The same was true for patients with both weakness and abnormal CMAP (HR 4.773, 95 % CI 1.882-12.106, p = 0.001) (Fig. 3 ).
Discussion
We showed that reduced CMAP on screening electrophysiological testing 8 days after ICU admission in a heterogeneous population of critically ill patients is highly sensitive but not specific for weakness, with a high Table 2 Incidence of electrophysiological abnormalities on the first and second evaluation and their predictive value for intensive care unit-acquired weakness (ICUAW) The accuracy of simplified electrophysiological testing to detect critical illness polyneuropathy (CIP) or myopathy (CIM) as defined by extensive electrophysiological testing was evaluated previously. Latronico et al. found that peroneal nerve CMAP had high sensitivity [19, 24] and specificity [24] for such a diagnosis based on full electrophysiological testing. Moss et al. found that combining peroneal and sural amplitudes further increased accuracy [15] . The current study differs from previous investigations by assessing diagnostic properties of simplified electrophysiological screening for weakness and its predictive value for longer-term outcome.
We found that predictive properties of electrophysiological screening for weakness depend on the time after onset of critical illness when tests were performed. Normal CMAP 1 week after onset of critical illness allowed exclusion of weakness with a high NPV, but this property was not maintained later on. Our findings on early CMAP results correspond to other reports. Weber-Carstens et al. [25] found in 44 patients a sensitivity of 92 % and specificity of 44 %. Similarly, Wieske et al. found in 35 patients that both ulnar and peroneal CMAP reduction had 100 % sensitivity but respectively 0 and 31 % specificity to detect weakness [26] . This concurs with a higher incidence of electrophysiological abnormalities as compared to weakness in critical illness [27, 28] . The early high incidence of abnormal CMAP, presumed to reflect both myopathies and neuropathies, suggests that this electrophysiological finding captures more than the problem of weakness.
In contrast, abnormal SNAP documented later during critical illness, which may indicate neuropathy, allowed one to diagnose weakness with a high PPV, which has not been reported earlier. This high PPV of abnormal SNAP is in line with Lefaucheur et al. [29] who reported reduced SNAPs in 17/30 patients diagnosed with weakness about 2 weeks after onset of illness. Zifko et al. [30] found reduced SNAPs in 71 % of 62 patients with weakness 40 days after ICU admission. The higher incidence of abnormal SNAP in both studies as compared with our study is explained by the selection of weak patients, referred for electrophysiology rather than systematically screened.
We found a high PPV of SEA for weakness later during critical illness. This is in line with Weber-Carstens et al. [25] who reported a specificity of 93 % and sensitivity of 48 % for detection of weakness by SEA using repetitive weekly screening. SEA, which may occur both in neuropathy and myopathy [13] , develops later than abnormal CMAP [27, 31, 32] and incidence increases with duration of ICU stay [33, 34] . In two RCTs, tight glucose control reduced the incidence of SEA approximately by half [33, 34] . We here document a similar incidence as in the tight glucose control arm of these studies, possibly explained by the routine implementation of tight glucose control.
To the best of our knowledge, this study is the first to demonstrate that abnormal CMAP 8 days after ICU admission was independently associated with 1-year mortality. This was also independent of weakness. Earlier studies reported that electrophysiological signs of CIP and CIM were related to poor short-term prognosis, including prolonged ICU and hospital stay, prolonged mechanical ventilation, prolonged rehabilitation, and increased hospital mortality [15, [35] [36] [37] [38] [39] [40] , which we confirmed here. Others suggested that this merely reflected illness severity [19, 30] . One study of 50 patients also examined the association of electrophysiological abnormalities with 1-year mortality but did not find a significant effect, possibly related to lack of power [38] . Our findings that abnormal CMAP was independently associated with 1-year mortality, an outcome clearly exceeding the index hospitalization, are therefore novel. This opens perspectives for identification of patients who might benefit from future interventions to improve outcome. As such, electrophysiology appears to hold information required for screening tools for ICU-acquired weakness, as recently stated by the American Thoracic Society (ATS) [2] .
The reason why abnormal CMAP was related to 1-year mortality, independent of other risk factors, remains speculative as we did not prospectively evaluate causes of death. The most obvious explanation that reduced CMAP predicts weakness, which by itself contributes to 1-year mortality, was invalidated as the association between reduced CMAP and 1-year mortality was independent of weakness. This suggests that CMAP reduction and weakness possibly identify different, though overlapping, phenotypes of neuromuscular involvement, as recently hypothesized [14] . Alternatively, this could point to subclinical weakness not captured by the MRC sum-score. CMAP reduction, reflecting derangement of excitable nerve/muscle tissue, can be an early biological sign, according to the theory of bioenergetic failure [19, 41] . Finally, reduced CMAPs could carry information about pathophysiological alterations determining longer-term outcome, not necessarily related to weakness. This should be further investigated mechanistically.
This study has some limitations and strengths. First, we only performed screening electrophysiological tests as we aimed to examine a large ICU population. Therefore, sophisticated tests such as direct muscle stimulation, which could have differentiated between neuropathy and myopathy [27, 29, 42, 43] and have both high sensitivity and specificity for weakness and may precede the diagnosis of weakness by a week [25] , were not feasible. For similar reasons, follow-up testing including voluntary muscle contraction was also not systematically performed. Hence, we cannot differentiate between the role of neuropathy and myopathy in the association with 1-year mortality. We also a priori chose to collect amplitudes as dichotomous data, analogously to other studies evaluating electrophysiology as a screening tool [19, 24] . In addition, we used alternative nerves if the standard nerves were not evaluable. As reference values depend on the nerves evaluated, dichotomization allowed us to cope with this issue. We cannot exclude that use of absolute values would have provided additional information. All electrophysiological data were protocolized by a single electrophysiologist, which may limit generalizability. The case-mix was mainly surgical ICU patients with 27.8 % cardiac surgery patients. Diagnostic properties may depend on case-mix and severity of weakness. Also, we cannot exclude bias from selection of patients who were screened as compared to those in whom patient or assessor was not available. Finally, we corrected as much as possible for premorbid risk factors and severity of illness. We cannot exclude that other unknown conditions brought about a reduced CMAP and contributed to the higher risk of 1-year mortality, as premorbid functional assessment or baseline nerve conduction studies were not available [15] . The strengths of this study are the large sample size, its prospective design, the systematic and repeated screening electrophysiology, and concomitant MRC sum-score measurements. There is no gold standard for diagnosing ICU-related neuromuscular complications but, as a more reliable test has not yet emerged, MRC sum-score below 48 was regarded as the reference standard by the ATS [2] .
In conclusion, early during critical illness, CMAP had a high NPV for the diagnosis of weakness, whereas SNAP and SEA later revealed a high PPV. One week after onset of critical illness, abnormal CMAP was the only electrophysiological characteristic associated with 1-year mortality, independent of weakness and other risk factors.
This suggests that CMAP may carry information about longer-term outcome and could be useful to identify patients for future interventional studies aiming to improve outcomes.
